Kaohsiung, Taiwan

Ming-Hung Ling

This inventor holds 1 USPTO granted patent. Top assignee: National Cheng-Kung University. Active years: 2018.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Ming-Hung Ling in Substance Delivery Technology

Introduction

Ming-Hung Ling is a notable inventor based in Kaohsiung, Taiwan. He has made significant contributions to the field of substance delivery technology. His innovative work focuses on enhancing the effectiveness of transdermal and transmucosal delivery techniques.

Latest Patents

Ming-Hung Ling holds a patent for a "Substance delivery device and substance delivery method using the same." This device comprises a substrate, a plurality of dissolvable supporting structures, and a plurality of carriers. The substrate is designed to attach to tissue, while the dissolvable supporting structures are positioned on the substrate. The carriers, which encapsulate substances, are placed on the dissolvable supporting structures. This invention is advantageous for providing a sustained release effect and improving the applicability of delivery techniques.

Career Highlights

Ming-Hung Ling is affiliated with National Cheng-Kung University, where he continues to advance his research in substance delivery systems. His work has garnered attention for its potential applications in medical and pharmaceutical fields.

Collaborations

Ming-Hung Ling has collaborated with notable colleagues, including Kuan-Ying Lai and Chun-Wei Lin. Their joint efforts contribute to the ongoing research and development in the area of substance delivery technologies.

Conclusion

Ming-Hung Ling's innovative contributions to substance delivery technology highlight his role as a key inventor in this field. His patent demonstrates the potential for improved delivery methods that can benefit various medical applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…